Published in Vaccine Weekly, November 29th, 2006
The 18% increase was due largely to increased revenue from the company's consumer services product lines, which grew 49% to $3.6 million for the third quarter of 2006, compared to $2.4 million in the year-ago period. Excluding non-recurring royalty payments, total revenue from the company's ongoing businesses increased 31% for the quarter.
Total medical services revenue for the third quarter 2006 decreased 14% compared to the same period last year, the result of an expected...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.